1. Updates on Outcomes for Novel T2D Therapies

3. An Emergence of Diabetes CVOT Data

4. Quality and Translatability of CVOT Data

5. DPP-4 Inhibitors Have Demonstrated CV Safety

6. Saxagliptin and Alogliptin Risk of Hospitalization for HF

7. Safety and Efficacy of DPP-4 Inhibitors to Date

8. The Known and Unknown Burden of Nonsevere Hypoglycemia

9. LEADER: Liraglutide

10. ELIXA: Lixisenatide

11. SUSTAIN-6: Semaglutide

12. Ongoing CVOTs With GLP-1 Receptor Agonists

13. Effects of GLP-1 Receptor Agonists Beyond Glucose Lowering

14. EMPA-REG OUTCOME: Empagliflozin

15. Updated Diabetes Guidelines

16. EMPA-REG OUTCOME Cardiovascular Outcomes

17. Patient Education: SGLT2 Inhibitors

18. EMPA-REG OUTCOME Renal Outcomes

19. The Continued Role of Metformin

20. PROactive Study Pioglitazone in Patients at High Risk for CV Events

21. IRIS Trial Pioglitazone in Patients With Insulin Resistance

22. Clinical Pearls From CVOT Data

23. Effect of Glucose Variability

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)